Octapharma Donates 30.5 Million International Units of Its Medicine Nuwiq to Treat People with Haemophilia in Developing Countries
2017: Octapharma is pleased to announce the completion of a charitable donation of 30.5 million international units of its human cell-line derived recombinant factor VIII product, Nuwiq®, in collaboration with Project SHARE, North Andover, Massachusetts (USA).
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005038/en/
Donation in Nepal of human cell-line derived recombinant factor VIII product Nuwiq (Photo: Business Wire)
Up to 75% of the world's estimated 400,000 people with haemophilia have little or no access to treatment that resolves life- and limb-threatening bleeds, and enables surgery and rehabilitation. A humanitarian program, Project SHARE facilitates the donation of blood-clotting factor products for the treatment of people with haemophilia in need of factor replacement therapy in countries where these medicines are scarce or still unavailable.
Over the last nine months, donations of Nuwiq® have been reaching seriously ill people in need in 16 countries: Armenia, Bahamas, Bangladesh, Barbados, Cambodia, Egypt, Ethiopia, Fiji, Kenya, Honduras, Myanmar, Nepal, Nicaragua, Philippines, Romania and Venezuela.
“We are deeply grateful to Octapharma for allowing us the privilege to serve those with haemophilia in developing countries who have limited or no access to treatment. These donations are saving lives,” said Laureen A. Kelley, the founder of Project SHARE.
“Octapharma has been committed to improving the lives of people with Haemophilia A since 1983. We are glad to continue our donation initiatives, providing access to patients with haemophilia in countries with little to no access to therapy,” remarked Olaf Walter, Board Member at Octapharma AG in Lachen, Switzerland.
“The haemophilia factor concentrates are used on patients suffering from serious joint and musculoskeletal complications and life-threatening bleeds,” said Walter Mwanda, Patron of the Kenya Haemophilia Association. “Assistance to one you do not know is great, and to a child is even greater. The Kenyans, mainly children living with haemophilia, thank you very much.”
“We cannot thank Octapharma and Project SHARE enough to for being so kind and generous,” said Suraksha Mani, of the Nepal Haemophilia Society. “We had limited factor stock when we received the Nuwiq® delivery. People in rural areas now have better access to factor concentrate. We believe this donation has already made positive changes in the lives of many people with haemophilia in Nepal. It has been life-saving and is helping to prevent disabilities.”
“This donation of Nuwiq® will help families with haemophilia in Honduras,” said Maria del Carmen of the Honduran Haemophilia Society. “The use of this medicine will serve families because their children and young people will have factor doses in their homes and therefore not miss classes in their schools and universities.”
Antonia Luque, Venezuelan Association for Haemophilia, added “We are currently going through a crisis for which we do not have the medicines that people need. There are currently 2185 people living with haemophilia A in Venezuela. Please accept our gratitude for such a valuable donation that will come to relieve cases of our population who are suffering from haemophilia A.”
About Haemophilia A
Haemophilia A is an X-linked hereditary disorder caused by factor VIII (FVIII) deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This rare disorder affects one in every 5,000 to 10,000 men worldwide. However, globally, 75% of haemophilia cases are still left undiagnosed or untreated.
About Nuwiq ®
Nuwiq® is a 4th generation rFVIII protein produced in a human cell line without chemical modification or fusion with any other protein. Nuwiq® is naturally suited to individually tailored prophylaxis while addressing immunogenicity in patients with haemophilia A. Nuwiq® is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTP, 190 individuals) with severe Haemophilia A, including 59 children. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned.
Disclaimer: All patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.
About Project SHARE
Project SHARE is a humanitarian program that donates blood-clotting medicine called factor to developing countries. Recipients are patients, doctors, clinics, and hospitals in countries where factor is scarce or unavailable. Project SHARE saves lives.
Project SHARE has donated more than 53 million units—approximately $53 million—of factor to thousands of patients in more than 70 developing countries.
For more information visit www.kelleycom.com/projectshare
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.
In 2016, the Group achieved €1.6 billion in revenue, an operating income of €383 million and invested €249 million to ensure future prosperity. Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:
- Haematology (coagulation disorders)
- Immunotherapy (immune disorders)
- Critical care
Octapharma owns six state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.
For more information visit www.octapharma.com
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Amobee Wins Auction Process to Acquire Videology Assets17.7.2018 13:13 | Pressemelding
Singtel subsidiary Amobee, a leading global digital marketing technology company serving brands and agencies, today announced that it has emerged as the winner in the court supervised auction to acquire certain assets from Videology, a software provider for advanced TV and video advertising, for purchase price of approximately US$101 million1. The purchase price is subject to adjustments for accounts receivable at closing, estimated to be approximately US$20.9 million. The acquisition, following Videology’s voluntary Chapter 11 restructuring proceedings, includes Videology’s technology platform, intellectual property and certain other assets of estimated net book value of US$5.3 million2. Over the past decade, Videology has emerged as a leading provider of software that empowers advertisers and publishers to use data to optimize campaigns and spend across digital platforms and television. The addition of Videology’s capabilities will be a further boost to Amobee’s omni-channel platform
Lenovo Leaps Forward with Next-Generation ThinkAgile Composable Cloud Platform17.7.2018 12:00 | Pressemelding
Lenovo Data Center Group (HKSE: 992) (ADR: LNVGY), one of the fastest growing hyperconverged infrastructure (HCI) vendors according to IDC, – with HCI revenue growing at almost twice the market growth rate in Q1 2018 (149.1% compared to 76.3%)—is further expanding its ThinkAgile portfolio to provide an innovative solution for customers who desire the agility of the public cloud and the security of a private cloud. To address this growing customer trend, Lenovo – together with Cloudistics – has developed the ThinkAgile CP Series composable cloud platform, a ‘cloud-in-a-box’ that offers all of the conveniences and ease-of-use of a public cloud environment secured behind the customer’s own data center firewall. Lenovo ThinkAgile CP Series – with fully-integrated infrastructure, application marketplace and end-to-end automation of software-defined network, compute and storage – delivers a turnkey cloud experience that can be easily and centrally managed from anywhere through a software-as-
JPMorgan Chase Bank launches offering of cash-settled exchangeable bonds into Ping An Insurance (Group) Company of China Limited due 202017.7.2018 12:00 | Pressemelding
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933) OR IN OR INTO JAPAN, THE PEOPLE’S REPUBLIC OF CHINA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. JPMorgan Chase Bank, N.A. (the “Issuer”) today announces the launch of an offering of cash-settled exchangeable bonds due 2020 (the “Bonds”) in aggregate principal amount of up to approximately USD 350 million. The Bonds are referable to H-shares (the “Shares”) of Ping An Insurance (Group) Company of China Limited (the “Company”). Exchange rights in respect of the Bonds will be cash-settled only. The Issuer is rated A+ (Stable outlook) by Standard & Poor’s, Aa3 (Stable outlook) by Moody’s and AA (Stable outlook) by Fitch. The Bonds will be issued in principal amounts of USD 200,000 and integral multiples of USD 100,000 in excess thereof and will not bear interest.
Greene Tweed Achieves Nadcap Accreditation for Non-Metallic Materials Testing17.7.2018 11:01 | Pressemelding
Greene Tweed’s Central Engineering (CE) Materials Test Lab recently completed its final Nadcap accreditation audit for Non-Metallic Materials Testing (NMMT) of composite materials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180717005200/en/ Greene Tweed Achieves Nadcap Accreditation (Photo: Greene Tweed) In support of Aerospace’s strategic initiative, this positions Greene Tweed as one of a select few aerospace companies who have attained this accreditation as validation of our materials testing capabilities and our position as a composite solutions provider. To achieve this standard, Greene Tweed’s CE lab completed a comprehensive audit against the highest standards for special process controls, test completion, and validation. This in-house accreditation adds to Greene Tweed’s responsiveness to new product development requests while expanding production material and customer product certification capabilities. It also
Norsk Titanium Collaborates with QuesTek Innovations LLC17.7.2018 11:00 | Pressemelding
Norsk Titanium (Norsk) and QuesTek Innovations LLC (QuesTek) announce a collaborative effort to test novel titanium alloys for applicability in additive manufacturing processes. As part of this collaboration, the companies are evaluating a QuesTek-designed titanium alloy using Norsk’s Rapid Plasma Deposition™ (RPD™) process. Preliminary evaluation of the alloy is complete and Norsk has manufactured initial test specimens. The test program will characterize the alloy microstructure, provide initial material properties, and will confirm QuesTek’s Ti alloy performance using Norsk’s proven production process. QuesTek’s patented titanium alloy has previously demonstrated approximately 15% greater strength and improved ductility over traditional Ti-6Al-4V in both wire-based Electron Beam Additive Manufacturing and traditional casting processes. "We are excited to be working closely with Norsk Titanium’s business and technical team to evaluate our alloy in their proven process. Based on our i
OpenGate Capital Signs Agreement to Acquire French, Belgium and Luxembourg Businesses from Gunnebo Group of Sweden17.7.2018 10:53 | Pressemelding
OpenGate Capital, a global private equity firm, announced today that it has signed a binding offer to acquire the French, Belgium and Luxembourg divisions of Gunnebo Group (GUNN: CPH), a leading provider of security products, services and solutions. The acquisition is expected to be completed in the fourth quarter of 2018. Terms of the transaction were not disclosed. Recognized as an integrated security solutions provider, the Gunnebo entities, which will be renamed post-closing, comprise two production sites and 12 sales branches in France, and a sales office in Luxembourg and Belgium. Throughout all regions, the business offers products and services across five lines: electronic security, security doors and partitions, safes and vaults, cash management and entrance control. The transaction will also include “Fichet Bauche,” a highly recognized name in quality safes and vaults. Gunnebo products and services are trusted security solutions chosen by a variety of customers including bank